ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
This article is part of the Research TopicNeuromuscular disorders: biomarkers, precision diagnosis, and targeted therapeuticsView all 5 articles
Expression profile of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple-seronegative myasthenia gravis
Provisionally accepted
- 1The First Affiliated Hospital of China Medical University, Shenyang, China
- 2China Medical University, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Triple-seronegative (Triple-SN) myasthenia gravis (MG) is a special subtype of MG, and its diagnosis and treatment face challenges. Our study aims to discover new biomarker, potential therapeutic target, and explore preliminary mechanism in triple-SN MG. Methods The study gathered peripheral blood mononuclear cells (PBMCs) of fifteen triple-SN MG patients who were newly diagnosed and fifteen healthy controls, applying various experimental techniques and analysis methods such as PBMCs isolation, analysis of microarray, double luciferase reporter assay, quantitative real-time polymerase chain reaction (qRT-PCR), cells culture and transfection, etc. Results Our study identified 385 differentially expressed genes (DEmRNAs) and 361 differentially expressed lncRNAs (DElncRNAs) in triple-SN MG. Notably, lncRNA FAM225A, one of the top five down-regulated DElncRNAs, was verified to decrease and negatively related to the clinical severity of triple-SN MG. Functional enrichment analysis, immune infiltration analysis and further experiments discovered that FAM225A affected the imbalance of Th1/Th2 by targeting hsa-miR-150-5p in the the pathogenesis of triple-SN MG. Conclusions This study was the first to provide important clues for understanding the pathological mechanism of triple-SN MG, which might contribute to discover novel diagnostic and therapeutic monitoring biomarker, and new target for treatment of triple-SN MG.
Keywords: Immune infiltration, long non-coding RNA, miR-150-5p, T cell differentiation, triple-seronegative myasthenia gravis
Received: 11 Jul 2025; Accepted: 03 Dec 2025.
Copyright: © 2025 Hao, CHEN, Wang, Yang, Zhu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ruixia Zhu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.